NasdaqGM:RAPTBiotechs
RAPT Therapeutics (RAPT) Is Up 8.0% After Index Additions And Trial Progress News Has The Bull Case Changed?
In December 2025, RAPT Therapeutics, Inc. was added to both the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index, following recent clinical and financing milestones.
This index inclusion underscores how ozureprubart’s progress, combined with a US$250,000,000 equity raise extending cash runway into mid-2028, is sharpening investor focus on RAPT’s pipeline.
We’ll now examine how ozureprubart’s Phase 2b food allergy trial clearance shapes RAPT Therapeutics’...